BioCryst Pharmaceuticals Inc (BCRX)
7.255
-0.09
(-1.23%)
USD |
NASDAQ |
Nov 05, 11:16
BioCryst Pharmaceuticals Research and Development Expense (Annual): 216.57M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 216.57M |
| December 31, 2022 | 253.30M |
| December 31, 2021 | 208.81M |
| December 31, 2020 | 122.96M |
| December 31, 2019 | 107.07M |
| December 31, 2018 | 84.89M |
| December 31, 2017 | 66.96M |
| December 31, 2016 | 61.01M |
| December 31, 2015 | 72.76M |
| December 31, 2014 | 51.80M |
| December 31, 2013 | 41.94M |
| December 31, 2012 | 49.16M |
| December 31, 2011 | 57.25M |
| December 31, 2010 | 83.90M |
| Date | Value |
|---|---|
| December 31, 2009 | 72.30M |
| December 31, 2008 | 73.33M |
| December 31, 2007 | 94.05M |
| December 31, 2006 | 47.08M |
| December 31, 2005 | 23.64M |
| December 31, 2004 | 18.87M |
| December 31, 2003 | 11.52M |
| December 31, 2002 | 15.47M |
| December 31, 2001 | 13.09M |
| December 31, 2000 | 9.590M |
| December 31, 1999 | 7.70M |
| December 31, 1998 | 9.30M |
| December 31, 1997 | 10.60M |
| December 31, 1996 | 7.60M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
107.07M
Minimum
2019
253.30M
Maximum
2022
181.74M
Average
208.81M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Novavax Inc | 737.50M |
| AIM ImmunoTech Inc | 10.94M |
| Perspective Therapeutics Inc | 21.31M |
| Protalix BioTherapeutics Inc | 17.09M |
| Armata Pharmaceuticals Inc | 33.77M |